Monday, August 29, 2016
Inovio Pharmaceuticals has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.
Metrion Biosciences, a specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research. This Consortium comprises the University of Glasgow, the University of St. Andrews, NHS Greater Glasgow & Clyde (NHS-GGC), Metrion Biosciences, the Grünenthal Group in Germany, and the U.K. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), with vital support and facilitation by NHS Blood & Transplant (Scotland).
BioLineRx, a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and preclinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.
Evofem, a biotechnology company focused on the development and commercialization of women’s health products, has announced that patient enrollment has begun in their clinical study that will evaluate the effect and duration of Evofem’s proprietary vaginal gel, Amphora for bacterial vaginosis (BV), on vaginal pH.
BeiGene, a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has announced the appointment of Amy C. Peterson, M.D. as chief medical officer, Immuno-oncology.
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.
Biomedical Systems, a 40-year-old, family-owned, clinical trial provider to pharmaceutical, medical device, biotech and CROs, has announced a new partnership with digital health company Foundry Health of Chicago. The two companies will collaborate on the development of a proprietary cloud-based data management system that will allow sponsors immediate access to clinical trial data in real time.